Oncternal Therapeutics announces Prostate Cancer Scientific Advisory Board

Oncternal Therapeutics announced the establishment of its Prostate Cancer Scientific Advisory Board. The Prostate Cancer SAB is comprised of distinguished academic and industry leaders in the prostate cancer field, which will advise Oncternal as it develops its novel dual-acting androgen receptor inhibitor, ONCT-534. The members of the Oncternal Prostate Cancer SAB include: Johann de Bono, M.D., Ph.D. is Regius Professor of Cancer Research, and Professor in Experimental Cancer Medicine at The Institute of Cancer Research, London, and Director of the joint Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London. Evan Yu, M.D. is Professor and Section Head of Medical Oncology at the Fred Hutchinson Cancer Center and the University of Washington in Seattle. Scott Dehm, Ph.D. is Professor and Apogee Enterprises Chair in Cancer Research, Department of Laboratory Medicine and Pathology at the University Minnesota, Minneapolis. Gunnar Kaufmann, Ph.D. is Senior Vice President, Chief Scientific Officer and Head of Open Innovation at Kyowa Kirin, Inc., San Diego. Howard Soule, Ph.D. – pro-bono advisor – is Executive Vice President & Chief Science Officer at the Prostate Cancer Foundation, Santa Monica.